Calcitonin gene-related peptide is involved in the spinal processing of mechanosensory input from the rat's knee joint and in the generation and maintenance of hyperexcitability of dorsal horn neurons during development of acute inflammation

doi:10.1016/0306-4522(95)00473-4

Neuroscience

Volume 71, Issue 4, April 1996, Pages 1095-1109

https://doi.org/10.1016/0306-4522(95)00473-4 Get rights and content

Abstract

In an electrophysiological study in anaesthetized rats, the involvement of calcitonin gene-related peptide in the spinal processing of mechanosensory information from the normal and inflamed knee joint was investigated. Calcitonin gene-related peptide(8–37), a specific antagonist at calcitonin gene-related peptide 1 receptors was administered ionophoretically close to nociceptive neurons with input from the knee joint before, during, and after development of acute inflammation in the knee induced by the intra-articular injections of kaolin and carrageenan. Calcitonin gene-related peptide(8–37) selectively antagonized the effects of ionophoretically applied calcitonin gene-related peptide but not those of ionophoretically applied substance P, neurokinin A, and (R,S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid. Before inflammation, calcitonin gene-related peptide(8–37) reduced the responses to noxious pressure applied to the knee in 22 of 23 neurons; in 14 of 22 neurons, the responses to innocuous pressure were also reduced. In eight neurons calcitonin gene-related peptide(8–37) was administered during induction and in three periods within the first 90 min of inflammation. In these neurons the developing inflammation evoked a significantly smaller increase of the responses to innocuous and noxious pressure applied to the injected knee than in 13 control neurons which were not treated by the antagonist during induction of inflammation. In 16 of 16 neurons, calcitonin gene-related peptide(8–37) reduced the responses to innocuous and noxious pressure once inflammation and hyperexcitability of the spinal cord neurons were established.

These data show that calcitonin gene-related peptide is involved in the spinal processing of mechano-sensory input from the normal joint. Furthermore, this peptide and its spinal receptors significantly contribute to the generation and expression of inflammation-evoked hyperexcitability of spinal cord neurons during the development of inflammation. Finally, calcitonin gene-related peptide is involved in the maintenance of inflammation-evoked hyperexcitability. By these effects calcitonin gene-related peptide receptors may significantly contribute to the neuronal basis of hyperalgesia and allodynia associated with inflammation.

Reference (66)

BarthoL. et al.
Antagonism of the effects of calcitonin gene-related peptide and of capsaicin on the guinea-pig isolated ileum by human alpha-calcitonin gene-related peptide(8–37)
Neurosci. Lett.
(1991)
BiellaG. et al.
Facilitatory role of calcitonin gene-related peptide (CGRP) on excitation induced by substance P (SP) and noxious stimuli in rat spinal dorsal horn neurons. An iontophoretic study in vivo
Brain Res.
(1991)
CoderreT.J. et al.
Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence
Pain
(1993)
CollinE. et al.
Increased in vivo release of calcitonin gene-related peptide-like material from the spinal cord in arthritic rats
Pain
(1993)
CridlandR.A. et al.
Effects of intrathecal administration of neuropeptides on a spinal nociceptive reflex in the rat: VIP, galanin, CGRP, TRH, somatostatin and angiotensin
Neuropeptides
(1988)
DoughertyP.M. et al.
Infusion of substance P or neurokinin A by microdialysis alters responses of primate spinothalamic tract neurons to cutaneous stimuli and to ionophoretically released excitatory amino acids
Pain
(1995)
DoughertyP.M. et al.
Combined application of excitatory amino acids and substance P produces long-lasting changes in responses of primate spinothalamic tract neurons
Brain Res. Rev.
(1993)
DoughertyP.M. et al.
Neural changes in acute arthritis in monkeys—I. Parallel enhancement of responses of spinothalamic tract neurons to mechanical stimulation and excitatory amino acids
Brain Res. Rev.
(1992)
DubnerR. et al.
Activity-dependent neuronal plasticity following tissue injury and inflammation
Trends Neurosci.
(1992)
GaleazzaM.T. et al.
Changes in [¹²⁵I)hCGRP: binding in rat spinal cord in an experimental model of acute, peripheral inflammation
Brain Res.
(1992)

GarryM.G. et al.

Enhanced release of immunoreactive CGRP and substance P from spinal dorsal horn slices occurs during carrageenan inflammation

Brain Res.

(1992)

GoadsbyP.J.

Inhibition of calcitonin gene-related by h-CGRP(8–37) antagonizes the cerebral dilator response from nasociliary nerve stimulation in the rat

Neurosci. Lett.

(1993)

GreenP.G. et al.

Sensory neuropeptide interactions in the production of plasma extravasation in the rat

Neuroscience

(1992)

HaleyJ.E. et al.

Evidence for spinal N-methyl-d-aspartate receptor involvement in prolonged chemical nociception in the rat

Brain Res.

(1990)

HaneschU. et al.

Substance P and calcitonin gene-related peptide immunoreactivity in primary afferent neurons of the cat's knee joint

Neuroscience

(1991)

KarimianM. et al.

Plasma protein extravasation into the rat knee joint induced by calcitonin gene-related peptide

Neurosci. Lett.

(1994)

KuraishiY. et al.

Calcitonin gene-related peptide increases in the dorsal root ganglia of adjuvant arthritic rat

Peptides

(1989)

KuraishiY. et al.

Antinociception induced in rats by intrathecal administration of antiserum against calcitonin gene-related peptide

Neurosci. Lett.

(1988)

LeGrevesP. et al.

Calcitonin gene-related peptide is a potent inhibitor of substance P degradation

Eur. J. Pharmac.

(1985)

MaoJ. et al.

Calcitonin gene-related peptide enhances substance P-induced behaviors via metabolic inhibition: in vivo evidence for a new mechanism of neuromodulation

McCarthyP.W. et al.

Cell type and conduction velocity of rat primary sensory neurons with calcitonin gene-related peptide-like immunoreactivity

Neuroscience

(1990)

McMahonS.B. et al.

Central Hyperexcitability triggered by noxious inputs

Curr. Opin. Neurobiol.

(1993)

MileticV. et al.

Iontophoretic application of calcitonin gene-related peptide produces a slow and prolonged excitation of neurons in the cat lumbar dorsal horn

Brain Res.

(1988)

NanayamaT. et al.

Capsaicin-induced release of calcitonin gene-related peptide from dorsal horn slices is enhanced in adjuvant arthritic rats

Neurosci. Res.

(1989)

NeugebauerV. et al.

The involvement of N-methyl-d-aspartate (NMDA) and non-NMDA receptors in the responsiveness of rat spinal neurons with input from the chronically inflamed ankle

Neurosci. Lett.

(1994)

O'BrienC. et al.

Differences in the chemical expression of rat primary afferent neurons which innervate skin, muscle or joint

Neuroscience

(1989)

OkuR. et al.

Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats

Brain. Res.

(1987)

PohlM. et al.

In vivo release of calcitonin gene-related peptide-like material from the cervicotrigeminal area in the rat. Effects of electrical and noxious stimulation of the muzzle

Neuroscience

(1992)

van RossumD. et al.

Effect of guanine nucleotides and temperature on calcitonin gene-related peptide receptor binding sites in brain and peripheral tissues

Brain Res.

(1993)

RyuP.D. et al.

Actions of calcitonin gene-related peptide on rat spinal dorsal horn neurons

Brain Res.

(1988)

SchaibleH.-G. et al.

Intraspinal release of immunoreactive calcitonin gene-related peptide during development of inflammation in the joint in vivo—a study with antibody microprobes in cat and rat

Neuroscience

(1994)

SchaibleH.-G. et al.

Afferent and spinal mechanisms of joint pain

Pain

(1993)

SlukaK.A. et al.

Neural changes in acute arthritis in monkeys—III. Changes in substance P, calcitonin gene-related peptide and glutamate in the dorsal horn of the spinal cord

Brain Res. Rev.

(1992)

Cited by (98)

5.32 - Joint Pain
2020, The Senses: A Comprehensive Reference: Volume 1-7, Second Edition
The chapter describes the nociceptive system of the joint, and the generation of joint pain upon diseases in the joint. The generation of joint pain upon joint diseases considers three levels, namely pathological changes in the joint which cause hyperalgesia and pain, changes in the nociceptive system such as peripheral and central sensitization and neuropathic changes, and general/systemic factors which influence the nociceptive processing.
Inhibition of transmitter release and attenuation of anti-retroviral- associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca<sup>2+</sup> channel peptides
2012, Journal of Biological Chemistry
N-type Ca²⁺ channels (CaV2.2) are a nidus for neurotransmitter release and nociceptive transmission. However, the use of CaV2.2 blockers in pain therapeutics is limited by side effects resulting from inhibition of the physiological functions of CaV2.2 within the CNS. We identified an anti-nociceptive peptide (Brittain, J. M., Duarte, D. B., Wilson, S. M., Zhu, W., Ballard, C., Johnson, P. L., Liu, N., Xiong, W., Ripsch, M. S., Wang, Y., Fehrenbacher, J. C., Fitz, S. D., Khanna, M., Park, C. K., Schmutzler, B. S., Cheon, B. M., Due, M. R., Brustovetsky, T., Ashpole, N. M., Hudmon, A., Meroueh, S. O., Hingtgen, C. M., Brustovetsky, N., Ji, R. R., Hurley, J. H., Jin, X., Shekhar, A., Xu, X. M., Oxford, G. S., Vasko, M. R., White, F. A., and Khanna, R. (2011) Suppression of inflammatory and neuropathic pain by uncoupling CRMP2 from the presynaptic Ca²⁺ channel complex. Nat. Med. 17, 822–829) derived from the axonal collapsin response mediator protein 2 (CRMP2), a protein known to bind and enhance CaV2.2 activity. Using a peptide tiling array, we identified novel peptides within the first intracellular loop (CaV2.2(388–402), “L1”) and the distal C terminus (CaV1.2(2014–2028) “Ct-dis”) that bound CRMP2. Microscale thermophoresis demonstrated micromolar and nanomolar binding affinities between recombinant CRMP2 and synthetic L1 and Ct-dis peptides, respectively. Co-immunoprecipitation experiments showed that CRMP2 association with CaV2.2 was inhibited by L1 and Ct-dis peptides. L1 and Ct-dis, rendered cell-penetrant by fusion with the protein transduction domain of the human immunodeficiency virus TAT protein, were tested in in vitro and in vivo experiments. Depolarization-induced calcium influx in dorsal root ganglion (DRG) neurons was inhibited by both peptides. Ct-dis, but not L1, peptide inhibited depolarization-stimulated release of the neuropeptide transmitter calcitonin gene-related peptide in mouse DRG neurons. Similar results were obtained in DRGs from mice with a heterozygous mutation of Nf1 linked to neurofibromatosis type 1. Ct-dis peptide, administered intraperitoneally, exhibited antinociception in a zalcitabine (2′-3′-dideoxycytidine) model of AIDS therapy-induced and tibial nerve injury-related peripheral neuropathy. This study suggests that CaV peptides, by perturbing interactions with the neuromodulator CRMP2, contribute to suppression of neuronal hypersensitivity and nociception.
Determination of specific neuropeptides modulation time course in a rat model of osteoarthritis pain by liquid chromatography ion trap mass spectrometry
2011, Neuropeptides
Animal models are useful to evaluate pharmacological therapies to alleviate joint pain. The present study characterized central neuropeptides modulation in the monoiodoacetate (MIA) rat model. Animals receiving a single 3 mg MIA injection were euthanized at 3, 7, 14, 21 and 28 days post injection. Spinal cords were analyzed by liquid chromatography ion trap mass spectrometry. Up-regulations of the calcitonin gene-related peptide and substance P were observed starting on days 7 and 28 respectively, whereas big dynorphin_(1–32) content decreased significantly on day 14 in comparison to control animals (P < 0.05). Preclinical drug evaluations using this model should be conducted between 7 and 21 days post injection when the lesions resemble most to human osteoarthritis.
Keratinocyte expression of calcitonin gene-related peptide β: Implications for neuropathic and inflammatory pain mechanisms
2011, Pain
Citation Excerpt :
Calcitonin gene-related peptide (CGRP) is a well-conserved neuropeptide implicated in nociception, vasoregulation, inflammation, and epidermal homeostasis [5,9,25,34,45,46,53,73,87,91,92,99,106,109,111].
Calcitonin gene-related peptide (CGRP) is a vasodilatory peptide that has been detected at high levels in the skin, blood, and cerebrospinal fluid (CSF) under a variety of inflammatory and chronic pain conditions, presumably derived from peptidergic C and Aδ innervation. Herein, CGRP immunolabeling (IL) was detected in epidermal keratinocytes at levels that were especially high and widespread in the skin of humans from locations afflicted with postherpetic neuralgia (PHN) and complex region pain syndrome type 1 (CRPS), of monkeys infected with simian immunodeficiency virus, and of rats subjected to L5/L6 spinal nerve ligation, sciatic nerve chronic constriction, and subcutaneous injection of complete Freund’s adjuvant. Increased CGRP-IL was also detected in epidermal keratinocytes of transgenic mice with keratin-14 promoter driven overexpression of noggin, an antagonist to BMP-4 signaling. Transcriptome microarray, quantitative Polymerase Chain Reaction (qPCR), and Western blot analyses using laser-captured mouse epidermis from transgenics, monolayer cultures of human and mouse keratinocytes, and multilayer human keratinocyte organotypic cultures, revealed that keratinocytes express predominantly the beta isoform of CGRP. Cutaneous peptidergic innervation has been shown to express predominantly the alpha isoform of CGRP. Keratinocytes also express the cognate CGRP receptor components, Calcitonin receptor-like receptor (CRLR), Receptor activity-modifying protein 1 (RAMP1), CGRP-receptor component protein (RCP) consistent with known observations that CGRP promotes several functional changes in keratinocytes, including proliferation and cytokine production. Our results indicate that keratinocyte-derived CGRPβ may modulate epidermal homeostasis through autocrine/paracrine signaling and may contribute to chronic pain under pathological conditions.
Antagonism of 5-HT <inf>2A</inf> receptors inhibits the expression of pronociceptive mediator and enhances endogenous opioid mechanism in carrageenan-induced inflammation in rats
2011, European Journal of Pharmacology
We have recently reported that treatment with the 5-HT_2A receptor antagonist ketanserin in the inflamed paw raises the nociceptive threshold above normal level (hypoalgesia) and this response is naloxone-reversible. The present study aimed to investigate neurochemical changes at the site of inflammation and in dorsal root ganglia (DRG) and the spinal cord following the blockade of 5-HT_2A receptors. Intraplantar injection of ketanserin (20 μg) inhibited carrageenan-induced increase in CGRP immunoreactivity-positive neurons in DRG. On the other hand, administration of ketanserin (20 μg) and 5-HT (10 μg), but not vehicle, enhanced and inhibited recruitment of β-endorphin-expressing immune cells, respectively, in subcutaneous loci of inflamed hindpaw. Moreover, the treatment with ketanserin increased the number of endomorphine-containing cells in the inflamed paw and μ-opioid receptor-expressing neurons in DRG at L4–5 but reduced the expression of endomorphine in superficial layers of the lumbar spinal cord. The present study provided evidence at the cellular level showing that the blockade of 5-HT_2A receptors inhibited inflammation-associated increase in pronociceptive mediator, and that the pronociceptive property of 5-HT is mediated by the suppression of inflammation-activated opioid mechanism. Therefore, targeting the 5-HT_2A receptors in the site of inflammation may be a promising approach to inhibit inflammatory pain.
Gene Therapy for Chronic Neuropathic Pain: How Does It Work and Where Do We Stand Today?
2011, Pain Medicine
Chronic neuropathic pain has been an enigma to physicians and researchers for decades. A better understanding of its pathophysiology has given us more insight into its various mechanisms and possible treatment options. We now have an understanding of the role of various ionic channels, biologically active molecules involved in pain, and also the intricate pain pathways where possible interventions might lead to substantial pain relief. The recent research on laboratory animals using virus-based vectors for gene transfer at targeted sites is very promising and may lead to additional human clinical trials. However, one needs to be aware that this “novel” approach is still in its infancy and that many of its details need to be further elucidated. The purpose of this article is to thoroughly review the current available literature and analyze the deficiencies in our current knowledge.
Literature review.
After an extensive online literature search, a total of 133 articles were selected to synthesize a comprehensive review about chronic neuropathic pain and gene therapy in order to understand the concepts and mechanisms.
Most of the studies have shown benefits of gene therapy in animal models, and recently, phase 1 human trials using herpes simplex virus vector have started for intractable cancer pain.
Although animal data have shown safety and efficacy, and initial human trials have been promising, additional studies in humans are required to more completely understand the actual benefits and risks of using gene therapy for the treatment of chronic neuropathic pain.

View all citing articles on Scopus

View full text

Calcitonin gene-related peptide is involved in the spinal processing of mechanosensory input from the rat's knee joint and in the generation and maintenance of hyperexcitability of dorsal horn neurons during development of acute inflammation

Abstract

Neurosci. Lett.

Brain Res.

Pain

Pain

Neuropeptides

Pain

Brain Res. Rev.

Brain Res. Rev.

Trends Neurosci.

Brain Res.

Brain Res.

Neurosci. Lett.

Neuroscience

Brain Res.

Neuroscience

Neurosci. Lett.

Peptides

Neurosci. Lett.

Eur. J. Pharmac.

Neuroscience

Curr. Opin. Neurobiol.

Brain Res.

Neurosci. Res.

Neurosci. Lett.

Neuroscience

Brain. Res.

Neuroscience

Brain Res.

Brain Res.

Neuroscience

Pain

Brain Res. Rev.